Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 230
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025
Malaysia, Nigeria, Peru, Zambia, and the European Medicines Agency have approved CAB for PrEP; ViiV also made submissions in Canada, Colombia, and the United Kingdom. There are now 13 regulatory approvals and 15 additional submissions that are pending.
Prevention Option:
Biomedical HIV Prevention Summit and PrEP in Black America Summit
1,000+ community advocates, researchers, policy experts, federal public health leadership, medical and service providers attended the NMAC annual Biomedical HIV Prevention Summit in Seattle. The discussion and debate on PrEP access, especially for racial and ethnic minorities and key populations, PrEP research, care, policy and community-based programs are ones to follow.
Prevention Option:
For Us by Us: PrEP in Black America – A Master Plan for HIV Prevention in Black America
In the spirit of seeking change to ameliorate the devastating impact of HIV in Black communities through biomedical HIV prevention, Black leaders convened the “PrEP in Black America (PIBA) Summit” virtually and in person on September 13, 2022,...
Prevention Option:
The More We Know
Science and real-world experience continue to demand a re-assessment of our collective understanding of the safety and effectiveness of PrEP options for women, including oral, vaginal ring, and injectable options. For instance, a new paper in the Journal of the American Medical Association by Dr. Jeanne Marrazzo challenges the notion that cisgender women need to be “super-adherers” to achieve protection utilizing oral PrEP. In this webinar, we discussed this important paper and more.
Prevention Option:
Developments in the HIV Biomedical Prevention Pipeline & PrEP Implementation Issues
The European AIDS Treatment Group published a report covering two online discussions on the HIV biomedical prevention research & PrEP implementation issues for community educators and advocates. The report covers developments from the PREVENIR Cohort study, on long-Acting intramuscular PrEP, DoxyPEP, vaccine, as well as STI-PEP research. It also reviews challenges in the uptake of PrEP among women and in particular migrant women from sub-Saharan Africa and trans people.
Prevention Option:
Topic:
PxWire Volume 14, Issue No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Each issue includes updates, emerging issues and upcoming events.
Prevention Option:
Cumulative PrEP Initiations
In 2020, the world missed the UNAIDS’ goal of reaching 3 million PrEP users. The updated target for 2025 is 10 million. Is the 2025 target achievable based on the current trends in PrEP uptake?
Prevention Option:
PrEP Initiations by Country Worldwide
AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe.
Prevention Option:
Coalition to Accelerate Access to Long-Acting PrEP
The Coalition to Accelerate Access to Long-Acting PrEP brings together leading donors, agencies, and advocates aimed at a practical goal: jointly develop strategies and take coordinated action to identify and overcome access challenges to just-approved and future PrEP options. AVAC serves as the Secretariat.
Prevention Option:
showing 1-10 of 230